Ravi Amaravadi

Trials

Studies that name Ravi Amaravadi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:30 UTC. Open this list on ClinicalTrials.gov

• Early Ph1
  NCT07700121 · PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma

  Abramson Cancer Center at Penn Medicine · not yet recruiting · Unresectable or Metastatic Melanoma · principal investigator
• Ph2
  NCT04527549 · Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

  ECOG-ACRIN Cancer Research Group · terminated · Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 · principal investigator
• Ph1/Ph2
  NCT04464759 · A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

  Ravi Amaravadi, MD · active not recruiting · Melanoma · principal investigator
• Ph2
  NCT04329923 · The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)

  Ravi Amaravadi, MD · terminated · COVID-19 · principal investigator
• Ph1/Ph2
  NCT02257424 · Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

  Abramson Cancer Center at Penn Medicine · completed · Advanced BRAF Mutant Melanoma · principal investigator
• Ph2
  NCT02230306 · Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases

  Melissa Burgess, MD · terminated · Active Melanoma Brain Metastases · principal investigator
• Ph1
  NCT01897116 · A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma

  Abramson Cancer Center at Penn Medicine · completed · Melanoma · principal investigator
• Ph1/Ph2
  NCT01188499 · Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors

  TetraLogic Pharmaceuticals · completed · Cancer · principal investigator
• Ph1
  NCT00993239 · Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma

  TetraLogic Pharmaceuticals · completed · Cancer · principal investigator
• Ph1
  NCT00909831 · Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

  Abramson Cancer Center at Penn Medicine · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
• Ph1
  NCT00714181 · Hydroxychloroquine and Temozolomide in Treating Patients With Metastatic or Unresectable Solid Tumors

  Abramson Cancer Center at Penn Medicine · completed · Unspecified Adult Solid Tumor, Protocol Specific · principal investigator
• Ph2
  NCT00602576 · Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma

  Abramson Cancer Center at Penn Medicine · completed · Melanoma (Skin) · principal investigator
• Ph2
  NCT00589420 · Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy

  Abramson Cancer Center at Penn Medicine · completed · Prostate Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 08:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

• Resistance mechanisms to autophagy-modulating therapies
  R01CA266404 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2022 to 2026 · $654,478 awarded in 2026
  Same name and institution; not confirmed by an ID
• Cancer Therapeutics Program
  P30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2016 to 2023 · $83,257 awarded in 2023
  Grant number is on one of their registry trials
• Molecular mechanisms of BRAF inhibitor induced UPR and autophagy
  R01CA198015 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2015 to 2019 · $355,019 awarded in 2019
  Same name and institution; not confirmed by an ID
• HLTF gene silencing: a novel determinant of sensitivity to autophagy inhibition
  R01CA169134 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2013 to 2017 · $312,942 awarded in 2017
  Same name and institution; not confirmed by an ID
• Therapeutic approaches that target cancer cell metabolism
  K23CA120862 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2008 to 2012 · $137,295 awarded in 2012
  Same name and institution; not confirmed by an ID
• Autophagy inhibition as a therapeutic strategy for glioblastoma mutliforme
  R21CA133898 · NCI · UNIVERSITY OF PENNSYLVANIA · fiscal years 2008 to 2009 · $356,164 awarded in 2009
  Same name and institution; not confirmed by an ID

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• ECOG-ACRIN Network Group Operations Center
  U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · fiscal years 2014 to 2026
  Named on NCT04527549